These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 20139930)

  • 21. UK biotech sector loses flagship PowderJect to Chiron.
    Mitchell P
    Nat Biotechnol; 2003 Jul; 21(7):717. PubMed ID: 12833073
    [No Abstract]   [Full Text] [Related]  

  • 22. [Galderma relies on partnerships].
    Fournier F
    J Dtsch Dermatol Ges; 2003 Jan; 1(1):83. PubMed ID: 16285297
    [No Abstract]   [Full Text] [Related]  

  • 23. UK industry consolidation is slow despite big merger.
    Mitchell P
    Nat Biotechnol; 2003 Mar; 21(3):215. PubMed ID: 12610553
    [No Abstract]   [Full Text] [Related]  

  • 24. Antisoma-Roche deal--a new kind of buyout?
    Mitchell P
    Nat Biotechnol; 2003 Jan; 21(1):3. PubMed ID: 12511894
    [No Abstract]   [Full Text] [Related]  

  • 25. Hyseq-Variagenics merger signals end of the line.
    Hodgson J
    Nat Biotechnol; 2003 Jan; 21(1):5. PubMed ID: 12511895
    [No Abstract]   [Full Text] [Related]  

  • 26. European Commission takes on Big Pharma.
    den Exter A
    Lancet; 2009 Aug; 374(9690):599-600. PubMed ID: 19699998
    [No Abstract]   [Full Text] [Related]  

  • 27. Deborah Dunsire.
    Littlehales C
    Nat Biotechnol; 2008 Nov; 26(11):1211. PubMed ID: 18997752
    [No Abstract]   [Full Text] [Related]  

  • 28. Second-quarter biotech job picture.
    Francisco M
    Nat Biotechnol; 2015 Aug; 33(8):883. PubMed ID: 26252149
    [No Abstract]   [Full Text] [Related]  

  • 29. Biotechs hold their own in shifting industry.
    Mitchell P
    Nat Biotechnol; 2002 Nov; 20(11):1065-6. PubMed ID: 12410238
    [No Abstract]   [Full Text] [Related]  

  • 30. Going it alone.
    Senior M
    Nat Biotechnol; 2014 May; 32(5):411-4. PubMed ID: 24811507
    [No Abstract]   [Full Text] [Related]  

  • 31. Biotech in Italy.
    Biotechnol J; 2007 Mar; 2(3):298-300. PubMed ID: 17354217
    [No Abstract]   [Full Text] [Related]  

  • 32. Italian biotech too reliant on big pharma.
    Meldolesi A
    Nat Biotechnol; 2004 Aug; 22(8):1047. PubMed ID: 15309759
    [No Abstract]   [Full Text] [Related]  

  • 33. Genzyme-Sanofi buy out is second largest biotech deal ever.
    Ratner M
    Nat Biotechnol; 2011 Apr; 29(4):293-4. PubMed ID: 21478828
    [No Abstract]   [Full Text] [Related]  

  • 34. Biotech giant helps itself without swallowing Galapagos whole.
    Senior M
    Nat Biotechnol; 2019 Oct; 37(10):1104-1105. PubMed ID: 31578499
    [No Abstract]   [Full Text] [Related]  

  • 35. The shape of European business in 2003.
    Wagner M
    Med Device Technol; 2002 Dec; 13(10):8-10. PubMed ID: 12575520
    [No Abstract]   [Full Text] [Related]  

  • 36. From the analyst's couch: The outlook for biotech exits.
    Grimaldi A
    Nat Biotechnol; 2014 Mar; 32(3):227-8. PubMed ID: 24727772
    [No Abstract]   [Full Text] [Related]  

  • 37. Hatteras rounds up $90 million to lead biotech rebound in North Carolina.
    Erickson D
    Nat Biotechnol; 2015 Nov; 33(11):1121-2. PubMed ID: 26544128
    [No Abstract]   [Full Text] [Related]  

  • 38. Troubled UK biotech firm faces new probe.
    Masood E
    Nature; 1998 Apr; 392(6679):852. PubMed ID: 9582060
    [No Abstract]   [Full Text] [Related]  

  • 39. Genzyme deal set to alter biotech landscape.
    Ledford H
    Nature; 2011 Feb; 470(7335):449. PubMed ID: 21350458
    [No Abstract]   [Full Text] [Related]  

  • 40. Counterpoint: biotech needs more than DTC as usual.
    Mack J
    Nat Biotechnol; 2006 Mar; 24(3):267. PubMed ID: 16525380
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.